380 related articles for article (PubMed ID: 32891754)
1. Sodium-glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells.
Morita M; Kanasaki K
Diabetes Metab; 2020 Oct; 46(5):353-361. PubMed ID: 32891754
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ; Johnson EJ; Tuttle KR
Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics.
Packer M
Am J Kidney Dis; 2021 Feb; 77(2):280-286. PubMed ID: 32711072
[TBL] [Abstract][Full Text] [Related]
4. The tubular hypothesis of nephron filtration and diabetic kidney disease.
Vallon V; Thomson SC
Nat Rev Nephrol; 2020 Jun; 16(6):317-336. PubMed ID: 32152499
[TBL] [Abstract][Full Text] [Related]
5. Sodium glucose cotransporter 2 and the diabetic kidney.
Komala MG; Panchapakesan U; Pollock C; Mather A
Curr Opin Nephrol Hypertens; 2013 Jan; 22(1):113-9. PubMed ID: 23042029
[TBL] [Abstract][Full Text] [Related]
6. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
[TBL] [Abstract][Full Text] [Related]
7. Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update.
Novikov A; Vallon V
Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):50-8. PubMed ID: 26575393
[TBL] [Abstract][Full Text] [Related]
8. Glycolytic lactate in diabetic kidney disease.
Darshi M; Kugathasan L; Maity S; Sridhar VS; Fernandez R; Limonte CP; Grajeda BI; Saliba A; Zhang G; Drel VR; Kim JJ; Montellano R; Tumova J; Montemayor D; Wang Z; Liu JJ; Wang J; Perkins BA; Lytvyn Y; Natarajan L; Lim SC; Feldman H; Toto R; Sedor JR; Patel J; Waikar SS; Brown J; Osman Y; He J; Chen J; Reeves WB; de Boer IH; Roy S; Vallon V; Hallan S; Gelfond JA; Cherney DZ; Sharma K;
JCI Insight; 2024 Jun; 9(11):. PubMed ID: 38855868
[TBL] [Abstract][Full Text] [Related]
9. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
Packer M
Diabetes Obes Metab; 2020 May; 22(5):734-742. PubMed ID: 31916329
[TBL] [Abstract][Full Text] [Related]
10. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules.
Li J; Liu H; Takagi S; Nitta K; Kitada M; Srivastava SP; Takagaki Y; Kanasaki K; Koya D
JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32134397
[TBL] [Abstract][Full Text] [Related]
11. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Thomson SC; Vallon V
Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
[TBL] [Abstract][Full Text] [Related]
12. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
Panchapakesan U; Pegg K; Gross S; Komala MG; Mudaliar H; Forbes J; Pollock C; Mather A
PLoS One; 2013; 8(2):e54442. PubMed ID: 23390498
[TBL] [Abstract][Full Text] [Related]
13. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review.
Song J; Li X; Ni J
Kidney Blood Press Res; 2023; 48(1):599-610. PubMed ID: 37717569
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
15. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
16. A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors.
Kume S; Maegawa H
J Diabetes Investig; 2022 May; 13(5):765-767. PubMed ID: 35029051
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Silva Dos Santos D; Polidoro JZ; Borges-JĂșnior FA; Girardi ACC
Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
[TBL] [Abstract][Full Text] [Related]
18. Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease.
Tuttle KR; Cherney DZ;
Clin J Am Soc Nephrol; 2020 Feb; 15(2):285-288. PubMed ID: 31740570
[No Abstract] [Full Text] [Related]
19. Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.
Packer M
J Am Soc Nephrol; 2020 May; 31(5):907-919. PubMed ID: 32276962
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
Kashiwagi A; Maegawa H
J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]